Veradermics (MANE) Other Accumulated Expenses (2025 - 2026)
Veradermics posted quarterly Other Accumulated Expenses of $39000.0 for Q1 2026, down 17.02% on a QoQ basis from $47000.0 in Q4 2025.
Veradermics (MANE) has 2 years of Other Accumulated Expenses data on file, last reported at $39000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $39000.0; the trailing twelve-month figure through Mar 2026 stood at $39000.0 (changed N/A YoY), and the FY2025 full-year result was $47000.0, changed N/A from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $39000.0, down from $47000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $47000.0 in Q4 2025 and bottomed at $39000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | 47,000.00 |